Patients experienced significant improvement over the course of the trial
Psoriasis treatment Ilumetri (Ilumya) has been found effective in a clinical trial, significantly improving nail psoriasis severity.
Ilumetri was developed for the treatment of moderate-to-severe psoriasis affecting the nails, a condition affects about 50% of plaque psoriasis patients.
"Nail psoriasis is understood as a difficult to treat population, and many current therapies fall short of providing lasting relief or are slow to produce results," said the study’s lead investigator Dr Paul Yamauchi.
Sun Pharmaceutical Industries USA, a subsidiary of the Indian pharmaceutical company, developed the medication and presented the results of the 99-patient, phase 3b placebo-controlled clinical trial at this year’s AAD Conference.
Those treated with Ilumetri demonstrated a 75% improvement from baseline, with nearly 30% of patients achieving at nails with minimal or no psoriasis. This is higher than the 4.2% of placebo patients.
"These data, along with our existing data in scalp psoriasis, reinforces the benefits of Ilumetri in difficult-to-treat populations,” said Sun Pharma North America’s senior vice president and head of development Dr Marek Honczarenko.
Ilumetri is a humanised lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23), a cytokine that plays a key role in inflammatory and autoimmune diseases.
By binding onto IL-23, the antibody inhibits the subunit’s interaction with the receptor, preventing the release of pro-inflammatory cytokines and chemokines.
"While other IL-23 inhibitors do not have a dedicated study to evaluate efficacy in nail psoriasis, these trial results clearly demonstrate the promise for Ilumetri to ease discomfort and improve patient outcomes,” said Yamauchi.
Ilumetri is for adults who are candidates for systematic therapy or phototherapy in the USA, as well as moderate-to-severe plaque psoriasis patients in Australia and Japan. The medication is called Ilumya outside of Europe.
